 Peter Kennealey
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 7 | 2024 | 670 | 1.200 |
Why?
| | Kidney Failure, Chronic | 5 | 2024 | 547 | 0.980 |
Why?
| | Thrombelastography | 4 | 2023 | 150 | 0.920 |
Why?
| | Tissue Plasminogen Activator | 2 | 2023 | 221 | 0.790 |
Why?
| | Pancreas Transplantation | 2 | 2018 | 75 | 0.720 |
Why?
| | Organ Transplantation | 5 | 2023 | 228 | 0.720 |
Why?
| | Blood Coagulation | 2 | 2023 | 238 | 0.660 |
Why?
| | Renal Dialysis | 3 | 2023 | 423 | 0.600 |
Why?
| | HLA Antigens | 1 | 2019 | 234 | 0.590 |
Why?
| | Carotid Arteries | 1 | 2019 | 196 | 0.590 |
Why?
| | Liver Transplantation | 5 | 2024 | 831 | 0.580 |
Why?
| | Simulation Training | 1 | 2018 | 82 | 0.530 |
Why?
| | General Surgery | 1 | 2018 | 152 | 0.520 |
Why?
| | Vascular Surgical Procedures | 1 | 2018 | 294 | 0.470 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 437 | 0.440 |
Why?
| | Tissue and Organ Procurement | 4 | 2024 | 288 | 0.400 |
Why?
| | Peritoneal Dialysis | 2 | 2024 | 95 | 0.390 |
Why?
| | Clinical Competence | 1 | 2018 | 1010 | 0.350 |
Why?
| | Resuscitation | 2 | 2024 | 237 | 0.340 |
Why?
| | Hernia, Ventral | 1 | 2009 | 23 | 0.310 |
Why?
| | Graft Survival | 5 | 2018 | 511 | 0.300 |
Why?
| | Catheters, Indwelling | 2 | 2024 | 79 | 0.270 |
Why?
| | Living Donors | 3 | 2021 | 287 | 0.260 |
Why?
| | Tissue Donors | 3 | 2024 | 391 | 0.240 |
Why?
| | Laparoscopy | 3 | 2024 | 451 | 0.230 |
Why?
| | Informed Consent | 1 | 2024 | 168 | 0.200 |
Why?
| | Directed Tissue Donation | 1 | 2021 | 4 | 0.190 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.180 |
Why?
| | Middle Aged | 10 | 2024 | 31075 | 0.180 |
Why?
| | Reperfusion | 1 | 2020 | 38 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2024 | 864 | 0.170 |
Why?
| | Humans | 27 | 2024 | 129219 | 0.170 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 45 | 0.170 |
Why?
| | Kidney Function Tests | 1 | 2020 | 152 | 0.170 |
Why?
| | Female | 16 | 2024 | 68607 | 0.170 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 82 | 0.170 |
Why?
| | Male | 14 | 2024 | 63498 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 327 | 0.160 |
Why?
| | Registries | 2 | 2024 | 1886 | 0.150 |
Why?
| | Adult | 10 | 2024 | 35471 | 0.150 |
Why?
| | Prospective Studies | 4 | 2020 | 7103 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 167 | 0.150 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1944 | 0.150 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 149 | 0.140 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 401 | 0.140 |
Why?
| | Family | 1 | 2021 | 653 | 0.140 |
Why?
| | Cattle | 1 | 2019 | 977 | 0.130 |
Why?
| | Death | 2 | 2023 | 121 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2011 | 538 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2024 | 14488 | 0.120 |
Why?
| | Diabetes Complications | 1 | 2016 | 223 | 0.120 |
Why?
| | Diabetic Nephropathies | 1 | 2018 | 284 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2024 | 10189 | 0.110 |
Why?
| | Aged | 6 | 2024 | 22030 | 0.110 |
Why?
| | Postoperative Complications | 3 | 2024 | 2476 | 0.110 |
Why?
| | Catheterization | 2 | 2024 | 175 | 0.100 |
Why?
| | Polytetrafluoroethylene | 1 | 2011 | 24 | 0.090 |
Why?
| | Vascular Patency | 1 | 2011 | 102 | 0.090 |
Why?
| | Fibrinolysis | 2 | 2023 | 137 | 0.090 |
Why?
| | Protons | 1 | 2011 | 80 | 0.090 |
Why?
| | Brain Death | 1 | 2010 | 46 | 0.090 |
Why?
| | Flavonoids | 2 | 2011 | 78 | 0.090 |
Why?
| | Blood Vessel Prosthesis | 1 | 2011 | 124 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3791 | 0.080 |
Why?
| | Waiting Lists | 2 | 2021 | 237 | 0.080 |
Why?
| | United States | 5 | 2024 | 13873 | 0.080 |
Why?
| | Piperidines | 2 | 2011 | 196 | 0.080 |
Why?
| | Surgical Mesh | 1 | 2009 | 46 | 0.080 |
Why?
| | Internship and Residency | 1 | 2018 | 1049 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2011 | 813 | 0.070 |
Why?
| | Nephrectomy | 1 | 2009 | 160 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7061 | 0.070 |
Why?
| | Biocompatible Materials | 1 | 2011 | 395 | 0.070 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2006 | 46 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 68 | 0.060 |
Why?
| | Apoptosis | 3 | 2011 | 2501 | 0.060 |
Why?
| | Creatinine | 2 | 2023 | 490 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5394 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2011 | 751 | 0.050 |
Why?
| | Abdomen | 1 | 2024 | 118 | 0.050 |
Why?
| | Young Adult | 1 | 2019 | 12403 | 0.050 |
Why?
| | Canada | 1 | 2024 | 347 | 0.050 |
Why?
| | Platelet Count | 1 | 2022 | 82 | 0.050 |
Why?
| | Abdominal Pain | 1 | 2024 | 144 | 0.050 |
Why?
| | Organ Preservation | 1 | 2023 | 94 | 0.050 |
Why?
| | Platelet Transfusion | 1 | 2022 | 59 | 0.050 |
Why?
| | Perfusion | 1 | 2023 | 197 | 0.050 |
Why?
| | Patients | 1 | 2023 | 167 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2018 | 3627 | 0.050 |
Why?
| | Altruism | 1 | 2021 | 27 | 0.050 |
Why?
| | Kidney | 1 | 2009 | 1375 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 53 | 0.040 |
Why?
| | Adolescent | 1 | 2019 | 20378 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 44 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 90 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 111 | 0.040 |
Why?
| | Patient Selection | 2 | 2016 | 662 | 0.040 |
Why?
| | Animals | 2 | 2019 | 35219 | 0.040 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 2058 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 380 | 0.040 |
Why?
| | Survival Rate | 2 | 2016 | 1874 | 0.040 |
Why?
| | Aging | 1 | 2008 | 1774 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 551 | 0.040 |
Why?
| | Teratocarcinoma | 1 | 1995 | 2 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 6549 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1477 | 0.030 |
Why?
| | Cell Cycle | 2 | 2011 | 590 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5408 | 0.020 |
Why?
| | Choline Kinase | 1 | 2011 | 3 | 0.020 |
Why?
| | Choline-Phosphate Cytidylyltransferase | 1 | 2011 | 3 | 0.020 |
Why?
| | Phosphorus Isotopes | 1 | 2011 | 7 | 0.020 |
Why?
| | HCT116 Cells | 1 | 2011 | 78 | 0.020 |
Why?
| | Obesity | 1 | 2024 | 2876 | 0.020 |
Why?
| | Camptothecin | 1 | 2011 | 109 | 0.020 |
Why?
| | Neoplasms | 1 | 2004 | 2467 | 0.020 |
Why?
| | Angiography | 1 | 2009 | 195 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 2011 | 532 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 76 | 0.020 |
Why?
| | Brain Injuries | 1 | 2010 | 467 | 0.020 |
Why?
| | Benzamides | 1 | 2006 | 207 | 0.020 |
Why?
| | Graft Rejection | 1 | 2008 | 597 | 0.010 |
Why?
| | Body Water | 1 | 2004 | 18 | 0.010 |
Why?
| | Hydrogen | 1 | 2004 | 65 | 0.010 |
Why?
| | Down-Regulation | 1 | 2006 | 636 | 0.010 |
Why?
| | Piperazines | 1 | 2006 | 342 | 0.010 |
Why?
| | RNA Polymerase II | 1 | 2006 | 317 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 939 | 0.010 |
Why?
| | Pyrimidines | 1 | 2006 | 459 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1565 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 1710 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1206 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1415 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4886 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 3211 | 0.010 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 1995 | 132 | 0.010 |
Why?
| | Genes, p53 | 1 | 1995 | 70 | 0.010 |
Why?
| | Mice | 1 | 2011 | 16861 | 0.010 |
Why?
| | Cell Survival | 1 | 1995 | 1085 | 0.010 |
Why?
|
|
Kennealey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|